Interní Med. 2019; 21(3): 187-191 | DOI: 10.36290/int.2019.030

Thrombophilias – to test or not to test?

doc. MUDr. Jana Hirmerová, Ph.D.
II. interní klinika a Biomedicínské centrum, Lékařská fakulta v Plzni, Univerzita Karlova, Plzeň

Thrombophilia, i.e. disposition to thrombosis (usually meant venous thrombosis) is caused by the shift of haemostatic balance towards a prothrombotic direction. These disorders are inherited or acquired and are associated with various degree of the risk. Their usual pathogenetic mechanism is the deficiency of natural inhibitors of coagulant factors or, conversely, the elevated level or activity of coagulant factors. Laboratory tests for the diagnostics of thrombophilia are often ordered as a part of differential diagnostic process in idiopathic venous thromboembolism. However, thrombophilia testing should be rational, ordered in selected patients only, with correct timing and, especially, only after careful consideration of potential practical benefit of testing for the patient and/or for his/her family members.

Keywords: thrombophilia, venous thromboembolism, laboratory tests, guidelines

Published: June 30, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hirmerová J. Thrombophilias – to test or not to test? Interní Med. 2019;21(3):187-191. doi: 10.36290/int.2019.030.
Download citation

References

  1. López JA, Chen J. Pathophysiology of venous thrombosis. Thromb Res. 2009; 123 Suppl 4: S30-34. Go to original source... Go to PubMed...
  2. Meissner MH. The epidemiology of and risk factors for acute deep venous thrombosis. V: Gloviczki P. Handbook of Venous Disorders, 3rd edition, Hodder Arnold, London, UK 2009: 94-104. Go to original source...
  3. Khan S, Joseph D Dickerman JD. Hereditary thrombophilia. Thrombosis Journal 2006, 4: 15. Go to original source... Go to PubMed...
  4. Rajendran P, Rengarajan T, Thangavel J et al. The vascular endothelium and human diseases. Int J Biol Sci. 2013 Nov 9; 9(10): 1057-1069. Go to original source... Go to PubMed...
  5. Segall JA, Liem TK. Congenital and acquired hypercoagulable syndromes. V: Bergan JJ. The Vein Book. Elsevier Academic Press 2007: 339-346. Go to original source...
  6. Di Minno MN, Ambrosino P, Ageno W et al. Natural anticoagulants deficiency and the risk of venous thromboembolism: a meta-analysis of observational studies. Thromb Res. 2015; 135(5): 923-932. Go to original source... Go to PubMed...
  7. Foy P, Moll S. Thrombophilia: 2009 update. Curr Treat Options Cardiovasc Med. 2009 Apr; 11(2): 114-128. Go to original source... Go to PubMed...
  8. Nutescu EA, Michaud JB, Caprini JA. Evaluation of hypercoagulable states and molecular markers of acute venous thrombosis. V: Gloviszki P. Handbook of venous disorders. Third Edition. Guidelines of the American Venous Forum. Hodder Arnold, London, UK, 2009: 113-128 Go to original source...
  9. Heit JA. Thrombophilia: Common questions on laboratory assessment and management. Hematology 2007: 127-135. Go to original source... Go to PubMed...
  10. Nicolaides AN, Fareed J, Kakkar AK et al.Prevention and treatment of venous thromboembolism-International Consensus Statement. Int Angiol. 2013; 32(2): 111-260. Go to PubMed...
  11. Connors JM, Thrombophilia Testing and Venous Thrombosis. N Engl J Med 2017; 377: 1177-1187. Go to original source... Go to PubMed...
  12. Pruthi RK. Optimal utilization of thrombophilia testing. Int J Lab Hem. 2017; 39(Suppl. 1):104-110. Go to original source... Go to PubMed...
  13. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4(2): 295-306 Go to original source... Go to PubMed...
  14. Bank I, Libourel EJ, Middeldorp S Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost. 2005; 3(1):79-84 Go to original source... Go to PubMed...
  15. Undas A, Brozek J, Szczeklik A. Homocysteine and thrombosis: from basic science to clinical evidence. Thromb Haemost. 2005; 94(5): 907-915. Go to original source... Go to PubMed...
  16. Arepally GM. Heparin-induced thrombocytopenia. Blood. 2017; 129(21): 2864-2872. Go to original source... Go to PubMed...
  17. Leiba M, Sidi Y, Gur H et al. Behçet's disease and thrombophilia. Ann Rheum Dis 2001; 60: 1081-1085. Go to original source... Go to PubMed...
  18. Landolfi R, Di Gennaro L. (2011). Pathophysiology of thrombosis in myeloproliferative neoplasms. Haematologica, 96(2), 183-186. doi:10.3324/haematol.2010.038299 Go to original source... Go to PubMed...
  19. Van Bijnen ST, Van Heerde WL, Muus P. Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria. J Thromb Haemost. 2012; 10(1): 1-10 Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.